Table 4. Baseline Characteristics.
| Characteristic | Cohort 1/Expansion (n=31) | Cohort 2a (n=3) | All Patients (N = 34) |
|---|---|---|---|
|
| |||
| Median age, y (range) | 66 (41-85) | 55 (39-77) | 66 (39-85) |
|
| |||
| Age ≥65 y, n (%) | 18 (58) | 1 (33) | 19 (56) |
|
| |||
| Male, n (%) | 16 (52) | 2 (67) | 18 (53) |
|
| |||
| Median BSA, m2 (range) | 1.82 (1.49-2.45) | 2.00 (1.95-2.35) | 1.86 (1.49-2.45) |
|
| |||
| Histology at study entry, n (%) | |||
| MF | 17 (55) | 2 (67) | 19 (56) |
| Transformed MF | 10 (32) | 1 (33) | 11 (32) |
| Sézary syndrome | 3 (10) | 0 (0) | 3 (9) |
| Primary cutaneous ALCL, ALK– | 1 (3) | 0 (0) | 1 (3) |
|
| |||
| ECOG performance status 0/1/2, % | 68/16/16 | 67/33/0 | 68/18/15 |
|
| |||
| Median number of prior therapies (range) | 3 (1-12) | 4 (3-14) | 3.5 (1-14) |